No retraction, correction or concern found when last checked on Nov 3, 2026.

Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19

Liam Gaziano, Claudia Giambartolomei, Alexandre C. Pereira and 54 more

Nature Medicine · 2021

doi:10.1038/s41591-021-01310-z

Read free

References 60

1.
Horby P, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med. 2020.
Not in our library10.1056/nejmoa2021436
2.
Beigel JH, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020.
Not in our library10.1056/nejmoa2007764
3.
Kalil AC, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. New England Journal of Medicine. 2020.
Not in our library10.1056/nejmoa2031994
4.
Nelson MR, et al. The support of human genetic evidence for approved drug indications. Nat Genet. 2015;47:856-860.
Not in our library10.1038/ng.3314
5.
Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264-1272.
Not in our library10.1056/nejmoa054013
6.
Lopalco L. CCR5: From Natural Resistance to a New Anti-HIV Strategy. Viruses. 2010;2:574-600.
Not in our library10.3390/v2020574
7.
Finan C, et al. The druggable genome and support for target identification and validation in drug development. Sci Transl Med. 2017;9.
Not in our library10.1126/scitranslmed.aag1166
8.
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis · 2012
No notice
9.
The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic · 2020
No notice
10.
Gaziano JM, et al. Million Veteran Program: A mega-biobank to study genetic influences on health and disease. J Clin Epidemiol. 2016;70:214-223.
Not in our library10.1016/j.jclinepi.2015.09.016
11.
Understanding the Assumptions Underlying Instrumental Variable Analyses: a Brief Review of Falsification Strategies and Related Tools · 2018
No notice
12.
The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45:580-585.
Not in our library10.1038/ng.2653
13.
Sun BB, et al. Genomic atlas of the human plasma proteome. Nature. 2018;558:73-79.
Not in our library10.1038/s41586-018-0175-2
14.
Genetic architecture of host proteins involved in SARS-CoV-2 infection · 2020
Corrected
15.
Borden EC, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov. 2007;6:975-990.
Not in our library10.1038/nrd2422
16.
Emilsson V, et al. Co-regulatory networks of human serum proteins link genetics to disease. Science. 2018;361:769-773.
Not in our library10.1126/science.aaq1327
17.
PhenoScanner: a database of human genotype–phenotype associations · 2016
No notice
18.
von Marschall Z, et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst. 2003;95:437-448.
Not in our library10.1093/jnci/95.6.437
19.
Jia H, et al. Endothelial cell functions impaired by interferon in vitro: Insights into the molecular mechanism of thrombotic microangiopathy associated with interferon therapy. Thromb Res. 2018;163:105-116.
Not in our library10.1016/j.thromres.2018.01.039
20.
Casassus P, et al. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol. 2002;119:1090-1097.
Not in our library10.1046/j.1365-2141.2002.03944.x
21.
Swanson SA, Tiemeier H, Ikram MA, Hernán MA. Nature as a Trialist?: Deconstructing the Analogy Between Mendelian Randomization and Randomized Trials. Epidemiology. 2017;28:653-659.
Not in our library10.1097/ede.0000000000000699
22.
Nelson CP, et al. Genetic Associations With Plasma Angiotensin Converting Enzyme 2 Concentration: Potential Relevance to COVID-19 Risk. Circulation. 2020;142:1117-1119.
Not in our library10.1161/circulationaha.120.049007
23.
Eliciting priors and relaxing the single causal variant assumption in colocalisation analyses · 2020
Corrected
24.
Hemnes AR, et al. A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension. Eur Respir J. 2018;51.
Not in our library10.1183/13993003.02638-2017
25.
Kuba K, Imai Y, Rao S, Jiang C, Penninger JM. Lessons from SARS: control of acute lung failure by the SARS receptor ACE2. J Mol Med (Berl). 2006;84:814-820.
Not in our library10.1007/s00109-006-0094-9
26.
Monteil V, et al. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell. 2020;181:905-913.
Not in our library10.1016/j.cell.2020.04.004
27.
Monteil V, et al. Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection. EMBO Mol Med. 2020;13:e13426.
Not in our library10.15252/emmm.202013426
28.
Zoufaly A, et al. Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir Med. 2020.
Not in our library10.1016/s2213-2600(20)30418-5
29.
Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment forPatients With COVID-19.
Not in our library
30.
Onabajo OO, et al. Interferons and viruses induce a novel truncated ACE2 isoform and not the full-length SARS-CoV-2 receptor. Nat Genet. 2020;52:1283-1293.
Not in our library10.1038/s41588-020-00731-9
31.
Blanco-Melo D, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020;181:1036-1045.
Not in our library10.1016/j.cell.2020.04.026
32.
Chu H, et al. Comparative Replication and Immune Activation Profiles of SARS-CoV-2 and SARS-CoV in Human Lungs: An Ex Vivo Study With Implications for the Pathogenesis of COVID-19. Clin Infect Dis. 2020;71:1400-1409.
Not in our library10.1093/cid/ciaa410
33.
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients · 2020
No notice
34.
Bastard P, et al. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020.
Not in our library10.1126/science.abd4585
35.
Zhang Q, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020.
Not in our library10.1126/science.abd4570
36.
van der Made CI, et al. Presence of Genetic Variants Among Young Men With Severe COVID-19. Jama. 2020;324:1-11.
Not in our library10.1001/jama.2020.13719
37.
Pairo-Castineira E, et al. Genetic mechanisms of critical illness in Covid-19. Nature. 2020.
Not in our library10.1038/s41586-020-03065-y
38.
Lokugamage KG, et al. Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV. Journal of Virology. 2020;94:e01410-01420.
Not in our library10.1128/jvi.01410-20
39.
Mantlo E, Bukreyeva N, Maruyama J, Paessler S, Huang C. Antiviral activities of type I interferons to SARS-CoV-2 infection. Antiviral Res. 2020;179:104811.
Not in our library10.1016/j.antiviral.2020.104811
40.
Clementi N, et al. Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome-Coronavirus 2 In Vitro When Administered After Virus Infection. J Infect Dis. 2020;222:722-725.
Not in our library10.1093/infdis/jiaa350

All 60 references

Cited by papers we hold 4

The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods · 2023
No notice
Polymorphisms and mutations of ACE2 and TMPRSS2 genes are associated with COVID-19: a systematic review · 2022
Not checked
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2 · 2022
No notice
Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study · 2021
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.